S&P 500   5,254.35
DOW   39,807.37
QQQ   444.01
Stock market today: Asian shares are mostly higher after another set of Wall St records
Delta Airline’s Put Option Activity Isn’t Bad News
3 Value Stocks Too Small For Buffett’s Portfolio
Disney Stock Catches 3 Upgrades In a Single Week
7 Stocks That Will Drive the Weight Loss Drugs Market
Walgreens Boots Alliance: Deep Value With Nowhere to Go But Up
Krispy Kreme's Sweet Deal: McDonald's Partnership Sparks Growth?
S&P 500   5,254.35
DOW   39,807.37
QQQ   444.01
Stock market today: Asian shares are mostly higher after another set of Wall St records
Delta Airline’s Put Option Activity Isn’t Bad News
3 Value Stocks Too Small For Buffett’s Portfolio
Disney Stock Catches 3 Upgrades In a Single Week
7 Stocks That Will Drive the Weight Loss Drugs Market
Walgreens Boots Alliance: Deep Value With Nowhere to Go But Up
Krispy Kreme's Sweet Deal: McDonald's Partnership Sparks Growth?
S&P 500   5,254.35
DOW   39,807.37
QQQ   444.01
Stock market today: Asian shares are mostly higher after another set of Wall St records
Delta Airline’s Put Option Activity Isn’t Bad News
3 Value Stocks Too Small For Buffett’s Portfolio
Disney Stock Catches 3 Upgrades In a Single Week
7 Stocks That Will Drive the Weight Loss Drugs Market
Walgreens Boots Alliance: Deep Value With Nowhere to Go But Up
Krispy Kreme's Sweet Deal: McDonald's Partnership Sparks Growth?
S&P 500   5,254.35
DOW   39,807.37
QQQ   444.01
Stock market today: Asian shares are mostly higher after another set of Wall St records
Delta Airline’s Put Option Activity Isn’t Bad News
3 Value Stocks Too Small For Buffett’s Portfolio
Disney Stock Catches 3 Upgrades In a Single Week
7 Stocks That Will Drive the Weight Loss Drugs Market
Walgreens Boots Alliance: Deep Value With Nowhere to Go But Up
Krispy Kreme's Sweet Deal: McDonald's Partnership Sparks Growth?
NASDAQ:GNTA

Genenta Science (GNTA) Stock Price, News & Analysis

$3.50
-0.16 (-4.37%)
(As of 03/28/2024 ET)
Today's Range
$3.30
$3.86
50-Day Range
$3.14
$4.49
52-Week Range
$3.11
$6.81
Volume
7,416 shs
Average Volume
4,704 shs
Market Capitalization
$63.77 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
N/A

Genenta Science MarketRank™ Stock Analysis

Analyst Rating
N/A
Upside/​Downside
N/A
Short Interest
Healthy
0.02% of Shares Sold Short
Dividend Strength
N/A
Sustainability
N/A
News Sentiment
1.44mentions of Genenta Science in the last 14 days
Based on 2 Articles This Week
Insider Trading
N/A
Proj. Earnings Growth
Decreasing
From ($0.56) to ($0.93) Per Share

Overall MarketRank

New Rank-Based ScoringMarketRank is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.

1.00 out of 5 stars

Medical Sector

836th out of 938 stocks

Biological Products, Except Diagnostic Industry

139th out of 149 stocks

GNTA stock logo

About Genenta Science Stock (NASDAQ:GNTA)

Genenta Science S.p.A., a clinical-stage biotechnology company, engages in the development of hematopoietic stem cell gene therapies for the treatment of solid tumors in Italy. Its lead product candidate is Temferon, which is in Phase 1/2a clinical trials for use in the treatment of glioblastoma multiforme in patients with unmethylated MGMT gene promoter. The company is also developing Temferon for use in the treatment of other solid tumor indications, locally advanced hepatocellular carcinoma, and intra-hepatic cholangiocarcinoma. In addition, it develops biologic platform to deliver immunomodulatory molecules directly to the tumor by infiltrating monocytes/macrophages. The company was incorporated in 2014 and is headquartered in Milan, Italy.

GNTA Stock Price History

GNTA Stock News Headlines

A lot of people are making this costly mistake
You may have heard the saying “options are risky” … And, they can be. But only if you use them the way a lot of folks do. A lot of people think of BUYING speculative options when they talk about options. And BUYING low probability, speculative options is definitely risky… It’s how some folks leverage large sums of money hoping that a stock moves in the “right” direction over a certain period of time.
Genenta Science S.p.A. (GNTA)
$25,000 into $109,616 in two months?
Today I want to show you how our research shows you could’ve grown a $25,000 account into $109,616.12 within the last TWO months. You see, former multi-million dollar hedge fund manager Roger Scott spent the better half of 2023 developing what might be the most advanced trading tool that exists… It’s a revolutionary software system that tracks the moves of institutional investors…. in real time…
Genenta Science S.p.A. ADR
See More Headlines
Receive GNTA Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Genenta Science and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Today
3/29/2024
Next Earnings (Estimated)
4/24/2024
Fiscal Year End
12/31/2024

Industry, Sector and Symbol

Sector
Medical
Industry
Biological products, except diagnostic
Sub-Industry
N/A
Current Symbol
NASDAQ:GNTA
Fax
N/A
Employees
4
Year Founded
N/A

Profitability

Pretax Margin
N/A

Debt

Sales & Book Value

Annual Sales
N/A
Book Value
$1.80 per share

Miscellaneous

Free Float
12,936,000
Market Cap
$63.77 million
Optionable
Not Optionable
Beta
0.79
20 Stocks to Sell Now Cover

MarketBeat has just released its list of 20 stocks that Wall Street analysts hate. These companies may appear to have good fundamentals, but top analysts smell something seriously rotten. Are any of these companies lurking around your portfolio? Find out by clicking the link below.

Get This Free Report

Key Executives

  • Mr. Pierluigi Paracchi (Age 51)
    Vice Chairman of the Board, CEO & GM
  • Dr. Luigi Naldini M.D. (Age 65)
    Ph.D., Co-Founder & Chairman of the Executive Scientific Board
  • Dr. Bernard Rudolph Gentner M.D. (Age 49)
    Ph.D., Co-Founder & Member of the Executive Scientific Board
  • Mr. Richard B. Slansky (Age 66)
    Chief Financial Officer
  • Dr. Carlo Russo M.D. (Age 71)
    Chief Medical Officer & Head of Development
  • Dr. Stefania Mazzoleni Ph.D. (Age 42)
    Director of Program Development
  • Ms. Barbara Regonini
    Director of Finance

GNTA Stock Analysis - Frequently Asked Questions

Should I buy or sell Genenta Science stock right now?

1 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Genenta Science in the last year. There are currently 1 buy rating for the stock. The consensus among Wall Street analysts is that investors should "buy" GNTA shares.
View GNTA analyst ratings
or view top-rated stocks.

How have GNTA shares performed in 2024?

Genenta Science's stock was trading at $4.95 at the start of the year. Since then, GNTA shares have decreased by 29.3% and is now trading at $3.5001.
View the best growth stocks for 2024 here
.

Are investors shorting Genenta Science?

Genenta Science saw a decline in short interest in March. As of March 15th, there was short interest totaling 3,300 shares, a decline of 5.7% from the February 29th total of 3,500 shares. Based on an average daily volume of 4,100 shares, the days-to-cover ratio is presently 0.8 days.
View Genenta Science's Short Interest
.

When is Genenta Science's next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Wednesday, April 24th 2024.
View our GNTA earnings forecast
.

When did Genenta Science IPO?

Genenta Science (GNTA) raised $28 million in an initial public offering (IPO) on Wednesday, December 15th 2021. The company issued 2,400,000 shares at a price of $10.50-$12.50 per share.

How do I buy shares of Genenta Science?

Shares of GNTA stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

This page (NASDAQ:GNTA) was last updated on 3/29/2024 by MarketBeat.com Staff

From Our Partners